title: Is it time to ReSET the standard for estrogen receptor testing in breast cancer?
authors.forename: Steffi
authors.initials: S
authors.lastname: Oesterreich
authors.forename: Adrian V
authors.initials: AV
authors.lastname: Lee
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D047628:Estrogen Receptor alpha / Q000235:genetics* / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D023281:Genomics / Q000379:methods; D006801:Humans; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014158:Transcription, Genetic; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha